TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis.

TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Rev Clin Immunol. 2019 Oct 25;: Authors: Lubrano E, Scriffignano S, Perrotta FM Abstract Introduction: Psoriatic Arthritis (PsA) is a chronic inflammatory disease characterized by psoriasis, synovitis, enthesitis, spondylitis and association with extra-articular manifestations and comorbidities. Treatment of PsA dramatically changed since the introduction of anti-TNF drugs which have shown to reduce the symptoms and signs of the disease and slow the radiographic progression. Despite the introduction of new molecules with different mechanisms of action, the role of anti-TNF in the treatment of all disease manifestations of this intriguing disease is still central. Areas covered: The aim of this paper is to review the role of anti-TNF drugs in the treatment of different disease domains in PsA (peripheral and axial joints, skin, enthesis, patient's reported outcomes, extra-articular manifestations), reporting data from randomized clinical trials and observational studies. An extensive literature search was performed on PubMed, with no limits or filters. The following search terms were used: "anti-TNF", "Psoriatic Arthritis". Expert opinion: Despite the emergence of different new treatments, anti-TNF therapy remains central in the management of all disease domains in PsA patients. PMID: 31652079 [PubMed - as supplied by publisher]
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research

Related Links:

Authors: Carli L, Calabresi E, Governato G, Braun J Abstract Spondyloarthritis (SpA) is the umbrella term for a broad spectrum of inflammatory rheumatic diseases with typical but also rather different clinical manifestations, limited laboratory abnormalities and characteristic imaging features. For classification purposes, a so-called non-radiographic form (nr-axSpA) is differentiated from a radiographic one (r-axSpA) which is almost identical to the classical ankylosing spondylitis (AS) that is genetically strongly associated with the major histocompatibility complex class 1 antigen HLA-B27. In axSpA, the axial sk...
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
ConclusionThe safety profile of adalimumab was consistent with previous findings and no new safety signals were observed.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Authors: Bakewell C, Aydin SZ, Ranganath VK, Eder L, Kaeley GS Abstract Psoriatic arthritis (PsA) affects up to 30% of patients with psoriasis and may include musculoskeletal manifestations such as enthesitis. Enthesitis is associated with joint damage, and early detection and treatment are essential to management of the disease. Traditionally assessed by clinical examination and conventional radiography, entheseal inflammation can now be more accurately assessed earlier in the disease using techniques such as ultrasound, magnetic resonance imaging, computed tomography, and molecular imaging. However, there is litt...
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
Abstract OBJECTIVE: The aim of this study was to compare patients with ankylosing spondylitis with psoriasis (ASP) and without psoriasis (AS), to axial PsA (axPsA) patients. METHODS: Two adult cohorts were recruited from the AS clinic: ASP and AS. These two cohorts were compared with two adult cohorts recruited from the PsA clinic: axPsA (radiographic sacroiliitis: ⩾bilateral grade 2 or unilateral grade 3 or 4); and Peripheral PsA. All patients were followed prospectively according to the same protocol. The demographic, clinical and radiographic variables were compared. Adjusted means were used to account f...
Source: Pain Physician - Category: Anesthesiology Authors: Tags: Rheumatology (Oxford) Source Type: research
ConclusionsThis multidisciplinary care unit has improved the care and satisfaction of patients with psoriasis or PsA, and increased collaboration between rheumatology and dermatology departments.ResumenObjetivoDescribir las características de los pacientes, la actividad registrada, así como la satisfacción percibida, de una consulta de atención multidisciplinar para pacientes con psoriasis o artritis psoriásica (APs).MétodosEstudio observacional retrospectivo con revisión de historias clínicas de todos los pacientes atendidos en la consulta de atención multidis...
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research
AbstractPurpose of ReviewThe purpose of this review is to educate the reader about the evolving classification of axial spondyloarthritis (AxSpA) and describe recent treatment data from clinical trials of medications with mechanisms of action other than TNF inhibition. The review will also address emerging treatment strategies for AxSpA.Recent FindingsNew and more sensitive classification schema for AxSpA find that the prevalence of the disease is more than twice that of the historic definition of ankylosing spondylitis (AS), when patients without radiographically observable damage to the sacroiliac joints are included. TN...
Source: Current Rheumatology Reports - Category: Rheumatology Source Type: research
AbstractTofacitinib (Xeljanz®) is the first Janus kinase (JAK) inhibitor approved at a dosage of 5  mg twice daily (BID) in the EU and the USA for the treatment of active psoriatic arthritis (PsA), where it is indicated in combination with methotrexate for patients who have had an inadequate response or who have been intolerant to a prior therapy with a disease-modifying antirheumatic drug (DMAR D). Two well-designed phase III trials (OPAL Broaden and OPAL Beyond) in patients with PsA with or without prior tumour necrosis factor inhibitor (TNFi) therapy showed that tofacitinib 5 mg BID (co-administered w...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
This article is protected by copyright. All rights reserved. PMID: 30820927 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
DiscussionAnkylosing spondylitis (also known as Bechterew disease and Marie Str ümpell disease). More common in males with 3:1 ratio.Spondyloarthritis is a group of diseases with common clinical, laboratory, and genetic features&association with human leukocyte antigen HLA-B27. Ankylosing spondylitis is the prototypic disease in the spectrum of spondyloarthritis which usually has axial skeletal manifestations. Other representative disorders in this spectrum of disease which usually have peripheral articular involvement, but axial skeleton manifestations are also frequently seen are --psori...
Source: Sumer's Radiology Site - Category: Radiology Authors: Source Type: blogs
Abstract The classification of axial spondyloarthritis (axSpA) comprises the classical ankylosing spondylitis (AS), which is characterized by already existing structural changes in the sacroiliac joints, and the so-called non-radiographic axSpA (nr-axSpA), in which by definition such changes are not present. This distinction is based on the ASAS classification criteria for axSpA, which are however not suitable for a diagnosis. According to the current classification, spondyloarthritis (SpA) includes axSpA, which can be associated with psoriasis and/or chronic inflammatory bowel diseases (CED), such as Crohn's dise...
Source: Zeitschrift fur Rheumatologie - Category: Rheumatology Authors: Tags: Z Rheumatol Source Type: research
More News: Allergy & Immunology | Arthritis | Clinical Trials | Psoriasis | Psoriatic Arthritis | Radiography | Rheumatology | Skin | Study